Pharma News

New partnerships: Biocon-Yoshindo and Syna-Intas

Home/Pharma News | Posted 25/11/2022

Biocon Biologics announced on 17 October 2022 that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals company Yoshindo for commercializing two of its pipeline biosimilar assets in Japan. Following this, on 2 November 2022, Syna Therapeutics signed an exclusive license agreement with Intas to commercialize a haematology biosimilar.

New funding to strengthen Cuba's biopharmaceutical industry

Home/Pharma News | Posted 18/11/2022

On 22 September 2022, the United Nations Development Programme (UNDP) announced the execution of a loan of 46.7 million euros (45.25 million dollars) to support Cuba's biopharmaceutical industry and improve the country's capacity to respond against diseases such as COVID-19.

Similis-Blau biosimilars development partnership announced

Home/Pharma News | Posted 04/11/2022

On 25 October 2022, JSR Life Sciences (and LLC (JSR)) have announced that their recently launched biosimilars development branch, Similis Bio, has signed a development and license agreement with Brazilian firm, Blau Farmacêutica. 

GaBI news digest for 14 October 2022

Home/Pharma News | Posted 14/10/2022

Selected news for the week of 14 October 2022 for GaBI readers.

FDA inspections in Iceland and Singapore for Alvotech and Strides

Home/Pharma News | Posted 14/10/2022

On 5 September 2022, Alvotech announced that it had received communication from the US Food and Drug Administration (FDA) that detailed the assessment of their Icelandic manufacturing facility and Alvotech’s subsequent written responses to FDA. This followed Strides announced the successful FDA inspection of their Singapore facility in early August 2022.

Novartis is set to spin-off Sandoz

Home/Pharma News | Posted 16/09/2022

Big pharma company Novartis announced on 25 August 2022 that it will spin off its generics and biosimilars arm, Sandoz.

New partnerships: Prestige-Intas and Samsung Bioepis-Samil

Home/Pharma News | Posted 02/09/2022

Prestige Biopharma (Prestige) and Intas Pharmaceuticals have entered a partnership to supply and commercialize Prestige Biopharma’s bevacizumab biosimilar in a number of countries globally. In addition, Samsung Bioepis has partnered with Samil to market their Lucentis (ranibizumab) biosimilar for ophthalmic diseases in South Korea.

Organon–Henlius partnership: biosimilars for women’s health

Home/Pharma News | Posted 24/06/2022

Organon, a global specialist in women’s health and expert in biosimilar commercialization, announced in mid-June 2022 that it had entered into an agreement with Shanghai Henlius Biotech, Inc. As part of this, Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab), and Prolia/Xgeva (denosumab) and will have global rights except for in China and its territories.

EMA authorizations: CRO generics suspended and Herceptin biosimilar refused

Home/Pharma News | Posted 17/06/2022

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorizations of several generics medicines tested by Synchron Research Services on 20 May 2022. The committee also refused the marketing authorization for BioPharma’s Herceptin biosimilar, Tuznue, on 19 May 2022.

Lupin–Yabao partnership to bring paediatric medicines to China

Home/Pharma News | Posted 20/05/2022

In April 2022, global pharmaceutical company, Lupin announced that it has entered a strategic partnership with China’s Yabao Pharmaceutical Company. Together, the companies will work to meet the growing demand for quality drugs with paediatric formulations in Chinese markets.